#United States #New York #Immunic #Aberdeen Investments #IMUX

Immunic, Inc. Completes $5.1 Million Equity Offering

New York, April 10, 2025 — Immunic, Inc. (NASDAQ: IMUX), a biotechnology firm dedicated to developing innovative treatments for chronic inflammatory and autoimmune diseases, has officially concluded a registered direct offering. This move, spearheaded by Aberdeen Investments, has resulted in the sale of 5,666,667 shares of its common stock, priced at $0.90 per share, leading to gross proceeds of approximately $5.1 million.

The funding gained from this offering will be pivotal for Immunic as it aims to propel its clinical trials and cover operational costs. Titan Partners Group, a division of American Capital Partners, played a crucial role as the sole placement agent for this offering.

This registered direct offering comes under a broader strategy that allows Immunic to utilize funds effectively for its ongoing and future clinical programs. The offering was executed under a shelf registration statement filed with the SEC on November 22, 2023, which became effective on May 31, 2024, thereby streamlining the process of raising capital through such offerings.

Immunic's portfolio includes a promising clinical pipeline, especially focusing on therapies for multiple sclerosis and inflammatory bowel diseases. Their lead candidate, vidofludimus calcium (IMU-838), is currently undergoing phase 3 trials for relapsing multiple sclerosis while also being tested in phase 2 for progressive types of the disease. Furthermore, the candidate has demonstrated therapeutic potential in patients with moderate-to-severe ulcerative colitis during earlier trials.

Operating at the forefront of biotechnology, Immunic employs advanced mechanisms to develop its treatments. Vidofludimus calcium functions as a first-in-class nuclear receptor-related 1 (Nurr1) activator, offering neuroprotective effects alongside anti-inflammatory and anti-viral properties through the inhibition of dihydroorotate dehydrogenase (DHODH).

A secondary candidate, IMU-856, specifically targets the protein Sirtuin 6 (SIRT6) to help restore intestinal barrier function. This molecule addresses conditions like celiac disease and inflammatory bowel disease, and it opens up possibilities for future applications.

Additionally, Immunic is working on IMU-381, a next-generation molecule that is in preclinical development, aimed at fulfilling the unmet needs in gastrointestinal disease treatment.

As Immunic moves forward with its fundraising and clinical trials, it's worth noting the inherent risks associated with biopharmaceutical development. The company has identified various factors that could influence its future performance, including clinical risks, market demand, and financial management. These factors underscore the importance of careful strategic planning as they work towards securing more favorable outcomes in their trials.

In summary, the successful closing of the $5.1 million offering reinforces Immunic's commitment to advancing its clinical programs. By leveraging this new capital, the company aims to continue developing innovative therapies that could significantly impact the lives of patients suffering from chronic inflammatory and autoimmune diseases. This capital infusion serves as a foundation for further scientific exploration and trial execution, positioning Immunic for the challenges and opportunities ahead.

For more information about Immunic and its clinical programs, you can visit www.imux.com.